Patent intelligence · US
US 11918565
Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions
Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions
Patent details — US 11918565
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 5, 2024
- Expiration
- Feb 29, 2044
- Applicant
- Pacira Pharmaceuticals, Inc.
- Claims
- 30
- CPC classes
- A61K, A61K31/44, A61K31/661, A61K47/543
Quick answer
US 11918565 (Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions) is held by Pacira Pharmaceuticals, Inc.. Status: granted. Granted Mar 5, 2024. Expires Feb 29, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Pacira Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 30
- CPC classes
- A61K, A61K31/44, A61K31/661, A61K47/543, A61K9/0019, A61K9/127
More from Pacira Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12370142
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12364764
Sustained release thermosetting gels comprising sodium channel blockers and the methods of making same
granted -
US 12318483
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12296047
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12285435
Multivesicular liposome formulations of dexamethasone
granted -
US 12285419
Bupivacaine multivesicular liposome formulations and uses thereof
granted -
US 12280149
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12251472
Manufacturing of bupivacaine multivesicular liposomes
granted
Frequently asked questions
What is US patent 11918565?
US 11918565 (Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions) is held by Pacira Pharmaceuticals, Inc.. Status: granted. Granted Mar 5, 2024. Expires Feb 29, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11918565?
Pacira Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 57 pharmaceutical patents for this assignee.
When does US 11918565 expire?
Our index shows an expiration date of Feb 29, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.